Log in
NYSE:TEVA

Teva Pharmaceutical Industries Stock Forecast, Price & News

$9.35
-0.09 (-0.95 %)
(As of 10/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$9.32
Now: $9.35
$9.49
50-Day Range
$8.57
MA: $9.17
$9.94
52-Week Range
$6.25
Now: $9.35
$13.76
Volume4.05 million shs
Average Volume6.47 million shs
Market Capitalization$10.21 billion
P/E Ratio4.05
Dividend YieldN/A
Beta1.48
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, the company provides specialty medicines for use in central nervous system and respiratory indications. Further, its products in the central nervous system and pain area comprise Copaxone for the treatment of relapsing forms of MS; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. Additionally, the company's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Braltus, Cinqair/Cinqaero, and AirDuo RespiClick/ArmonAir RespiClick/AirDuo Digihaler for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. It has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.
Read More
Teva Pharmaceutical Industries logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 3.8 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.28 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone972-3914-8171
Employees40,039

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$16.89 billion
Cash Flow$3.91 per share
Book Value$13.79 per share

Profitability

Net Income$-998,000,000.00

Miscellaneous

Outstanding Shares1,092,190,000
Market Cap$10.21 billion
Next Earnings Date11/5/2020 (Confirmed)
OptionableOptionable
$9.35
-0.09 (-0.95 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TEVA News and Ratings via Email

Sign-up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Teva Pharmaceutical Industries (NYSE:TEVA) Frequently Asked Questions

How has Teva Pharmaceutical Industries' stock price been impacted by COVID-19 (Coronavirus)?

Teva Pharmaceutical Industries' stock was trading at $9.01 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TEVA stock has increased by 3.8% and is now trading at $9.35.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Teva Pharmaceutical Industries?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 3 sell ratings, 9 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Teva Pharmaceutical Industries
.

When is Teva Pharmaceutical Industries' next earnings date?

Teva Pharmaceutical Industries is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Teva Pharmaceutical Industries
.

How can I listen to Teva Pharmaceutical Industries' earnings call?

Teva Pharmaceutical Industries will be holding an earnings conference call on Thursday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Teva Pharmaceutical Industries' earnings last quarter?

Teva Pharmaceutical Industries Limited (NYSE:TEVA) released its quarterly earnings results on Wednesday, August, 5th. The company reported $0.55 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.53 by $0.02. The firm earned $3.87 billion during the quarter, compared to analysts' expectations of $3.94 billion. Teva Pharmaceutical Industries had a net margin of 0.03% and a return on equity of 17.88%. The firm's revenue was down 7.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.60 EPS.
View Teva Pharmaceutical Industries' earnings history
.

What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?

Teva Pharmaceutical Industries issued an update on its FY20 earnings guidance on Wednesday, August, 5th. The company provided EPS guidance of $2.30 to $2.55 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.49. The company issued revenue guidance of $16.6 billion to $17 billion, compared to the consensus revenue estimate of $16.83 billion.

What price target have analysts set for TEVA?

17 Wall Street analysts have issued 12-month target prices for Teva Pharmaceutical Industries' shares. Their forecasts range from $8.00 to $16.00. On average, they anticipate Teva Pharmaceutical Industries' share price to reach $12.07 in the next year. This suggests a possible upside of 29.1% from the stock's current price.
View analysts' price targets for Teva Pharmaceutical Industries
.

Who are some of Teva Pharmaceutical Industries' key competitors?

What other stocks do shareholders of Teva Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Bank of America (BAC), Micron Technology (MU), Gilead Sciences (GILD), Johnson & Johnson (JNJ) and Cisco Systems (CSCO).

Who are Teva Pharmaceutical Industries' key executives?

Teva Pharmaceutical Industries' management team includes the following people:
  • Mr. Kare Schultz, Pres, CEO & Director (Age 59, Pay $5.6M)
  • Mr. Eliyahu Sharon Kalif, Exec. VP & CFO (Age 47, Pay $655.76k)
  • Dr. Hafrun Fridriksdottir, Exec. VP of Global R&D (Age 58, Pay $2.48M)
  • Mr. Brendan P. O'Grady, Exec. VP of North America Commercial (Age 53, Pay $1.56M)
  • Mr. Gianfranco Nazzi, Exec. VP of International Markets Commercial (Age 51, Pay $2.15M)

What is Teva Pharmaceutical Industries' stock symbol?

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Who are Teva Pharmaceutical Industries' major shareholders?

Teva Pharmaceutical Industries' stock is owned by many different retail and institutional investors. Top institutional investors include Harel Insurance Investments & Financial Services Ltd. (0.74%), Financial Sense Advisors Inc. (0.02%), Standard Life Aberdeen plc (0.01%), Nissay Asset Management Corp Japan ADV (0.01%), IFM Investors Pty Ltd (0.01%) and Envestnet Asset Management Inc. (0.01%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eric Drape, Hafrun Fridriksdottir, Luzich Partners Llc, Mark Sabag, Michael James Mcclellan, Notaristefani Carlo De, Richard Daniell, Rosemary A Crane, Sol J Barer and Sven Dethlefs.
View institutional ownership trends for Teva Pharmaceutical Industries
.

Which institutional investors are selling Teva Pharmaceutical Industries stock?

TEVA stock was sold by a variety of institutional investors in the last quarter, including Financial Sense Advisors Inc., Nissay Asset Management Corp Japan ADV, Pinnacle Associates Ltd., Standard Life Aberdeen plc, Wedbush Securities Inc., Redpoint Investment Management Pty Ltd, SOL Capital Management CO, and DAVENPORT & Co LLC. Company insiders that have sold Teva Pharmaceutical Industries company stock in the last year include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eric Drape, Hafrun Fridriksdottir, Mark Sabag, Michael James Mcclellan, Richard Daniell, and Rosemary A Crane.
View insider buying and selling activity for Teva Pharmaceutical Industries
.

Which institutional investors are buying Teva Pharmaceutical Industries stock?

TEVA stock was acquired by a variety of institutional investors in the last quarter, including Harel Insurance Investments & Financial Services Ltd., Envestnet Asset Management Inc., Brave Asset Management Inc., NuWave Investment Management LLC, NEXT Financial Group Inc, IFM Investors Pty Ltd, Pacer Advisors Inc., and DNB Asset Management AS.
View insider buying and selling activity for Teva Pharmaceutical Industries
.

How do I buy shares of Teva Pharmaceutical Industries?

Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Teva Pharmaceutical Industries' stock price today?

One share of TEVA stock can currently be purchased for approximately $9.35.

How big of a company is Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries has a market capitalization of $10.21 billion and generates $16.89 billion in revenue each year. The company earns $-998,000,000.00 in net income (profit) each year or $2.31 on an earnings per share basis. Teva Pharmaceutical Industries employs 40,039 workers across the globe.

What is Teva Pharmaceutical Industries' official website?

The official website for Teva Pharmaceutical Industries is www.tevapharm.com.

How can I contact Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at 972-3914-8171 or via email at [email protected]

This page was last updated on 10/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.